Click for new scientific resources and news about Corona[COVID-19]

Paper Information

Journal:   ACTA MEDICA IRANICA   2016 , Volume 54 , Number 6; Page(s) 352 To 358.
 
Paper: 

EVALUATION OF SD-208, A TGF-β-RI KINASE INHIBITOR, AS AN ANTICANCER AGENT IN RETINOBLASTOMA

 
 
Author(s):  FADAKAR PURAN, AKBARI ABOLFAZL, GHASSEMI FARIBA, MOBINI GHOLAMREZA, MOHEBI MASOUMEH, BOLHASSANI MANZAR, ABEDKHOJASTEH HODA, HEIDARI MANSOUR*
 
* DEPARTMENT OF MEDICAL GENETICS, SCHOOL OF MEDICINE, TEHRAN UNIVERSITY OF MEDICAL SCIENCES, TEHRAN, IRAN
 
Abstract: 
Retinoblastoma is the most common intraocular tumor in children resulting from genetic alterations and transformation of mature retinal cells. The objective of this study was to investigate the effects of SD-208, TGF-b-RI kinase inhibitor, on the expression of some miRNAs including a miR-17/92 cluster in retinoblastoma cells. Prior to initiate this work, the cell proliferation was studied by Methyl Thiazolyl Tetrazolium (MTT) and bromo-2?-deoxyuridine (BrdU) assays. Then, the expression patterns of four miRNAs (18a, 20a, 22, and 34a) were investigated in the treated SD-208 (0.0, 1, 2 and 3 mM) and untreated Y-79 cells. A remarkable inhibition of the cell proliferation was found in Y-79 cells treated with SD-208 versus untreated cells. Also, the expression changes were observed in miRNAs 18a, 20a, 22 and 34a in response to SD-208 treatment (P<0.05). The findings of the present study suggest that the anti-cancer effect of SD-208 may be exerted due to the regulation of specific miRNAs, at least in this particular retinoblastoma cell line. To the best of the researchers’ knowledge, this is the first report demonstrating that the SD-208 could alter the expression of tumor suppressive miRNAs as well as oncomiRsin vitro. In conclusion, the present data suggest that SD-208 could be an alternative agent in retinoblastoma treatment.
 
Keyword(s): MIRNA, RETINOBLASTOMA, SD-208, Y-79 CELL LINE
 
 
References: 
 
Citations: 
 
+ Click to Cite.
APA: Copy

FADAKAR, P., & AKBARI, A., & GHASSEMI, F., & MOBINI, G., & MOHEBI, M., & BOLHASSANI, M., & ABEDKHOJASTEH, H., & HEIDARI, M. (2016). EVALUATION OF SD-208, A TGF-β-RI KINASE INHIBITOR, AS AN ANTICANCER AGENT IN RETINOBLASTOMA. ACTA MEDICA IRANICA, 54(6), 352-358. https://www.sid.ir/en/journal/ViewPaper.aspx?id=510153



Vancouver: Copy

FADAKAR PURAN, AKBARI ABOLFAZL, GHASSEMI FARIBA, MOBINI GHOLAMREZA, MOHEBI MASOUMEH, BOLHASSANI MANZAR, ABEDKHOJASTEH HODA, HEIDARI MANSOUR. EVALUATION OF SD-208, A TGF-β-RI KINASE INHIBITOR, AS AN ANTICANCER AGENT IN RETINOBLASTOMA. ACTA MEDICA IRANICA. 2016 [cited 2021December02];54(6):352-358. Available from: https://www.sid.ir/en/journal/ViewPaper.aspx?id=510153



IEEE: Copy

FADAKAR, P., AKBARI, A., GHASSEMI, F., MOBINI, G., MOHEBI, M., BOLHASSANI, M., ABEDKHOJASTEH, H., HEIDARI, M., 2016. EVALUATION OF SD-208, A TGF-β-RI KINASE INHIBITOR, AS AN ANTICANCER AGENT IN RETINOBLASTOMA. ACTA MEDICA IRANICA, [online] 54(6), pp.352-358. Available: https://www.sid.ir/en/journal/ViewPaper.aspx?id=510153.



 
  pdf-File
Yearly Visit 48
 
 
Latest on Blog
Enter SID Blog